Core Viewpoint - The document outlines the management system for selecting and appointing accounting firms by Guangxi Liuyao Group Co., Ltd., aiming to enhance audit quality and protect shareholder interests [1]. Group 1: General Principles - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and specific management measures for state-owned enterprises and listed companies [1]. - The appointed accounting firm is responsible for auditing the company's financial reports, internal controls, and related information, providing audit opinions and reports [1]. Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess necessary qualifications as per national regulatory authorities and the China Securities Regulatory Commission [2]. - Firms should have a stable workplace, sound organizational structure, and robust internal management systems [2]. - They must be familiar with relevant financial laws and regulations and have a good reputation with no administrative penalties related to securities and futures business in the past three years [2]. Group 3: Procedures for Selecting Accounting Firms - The audit committee, independent directors, or a third of the board can propose the hiring of accounting firms [3]. - The audit committee is responsible for overseeing the selection process, including developing policies, initiating selection, and evaluating proposals [3][4]. - The selection process must ensure fairness and transparency, utilizing competitive negotiation, public selection, or invitation to tender [4]. Group 4: Evaluation Criteria for Selection - Evaluation criteria for selecting accounting firms include audit fee quotes, qualifications, performance records, quality management, work plans, and risk management capabilities [5]. - Quality management must account for at least 40% of the evaluation score, while audit fees should not exceed 15% [5]. Group 5: Special Provisions for Replacing Accounting Firms - The company must replace the accounting firm if there are significant quality defects, delays in audit work, or if the firm no longer meets the necessary qualifications [6][7]. - If a vacancy occurs during the annual audit period, the audit committee can propose a replacement firm to the board [8]. Group 6: Disclosure and Reporting Requirements - The company must disclose information about the accounting firm, including service duration and audit fees, in the annual report [9]. - Any significant changes in audit fees or the selection process must be reported, especially if fees decrease by 20% or more [10]. Group 7: Supervision and Penalties - The audit committee must monitor the selection process and report any violations of laws or regulations to the board [11]. - Serious violations by the accounting firm can lead to the company ceasing to appoint them for audit work [11].

Core Viewpoint - Haiwang Biological (SZ 000078) reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its financial performance [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 14.312 billion yuan, representing a year-on-year decrease of 13.95% [1] - The net profit attributable to shareholders was around 31.68 million yuan, down 30.23% compared to the previous year [1] - Basic earnings per share were 0.012 yuan, reflecting a decrease of 30.64% year-on-year [1]

Core Viewpoint - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.34 RMB per share, which represents 48.23% of the net profit attributable to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The company reported a net profit of 798,165,020.98 RMB for the first half of 2025 [1]. - The total cash dividend to be distributed is 384,922,717.94 RMB (including tax) [1]. - The distribution will be based on the total share capital registered on the equity distribution record date, excluding repurchased shares [1]. Decision-Making Process - The profit distribution plan was approved during the 27th meeting of the fourth board of directors on August 28, 2025 [2]. - The proposal will be submitted for review at the company's second extraordinary general meeting of shareholders in 2025 [2]. - The supervisory board believes the plan is reasonable and does not harm the interests of the company or its shareholders, especially minority shareholders [2].

Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. reported a steady growth in revenue and profit for the first half of 2025, driven by its innovative transformation and strong performance in both pharmaceutical manufacturing and commercial sectors [2][3]. Company Overview and Key Financial Indicators - The company achieved operating revenue of CNY 141.59 billion, a year-on-year increase of 1.56% [3]. - Total profit reached CNY 6.82 billion, reflecting a significant growth of 41.45% compared to the previous year [3]. - Net profit attributable to shareholders was CNY 4.46 billion, up 51.56% year-on-year [3]. - The company’s net assets amounted to CNY 75.10 billion, a 4.77% increase from the end of the previous year [3]. Business and Operational Highlights - The company focuses on pharmaceutical manufacturing and commercial operations, emphasizing innovation and efficiency [3][4]. - It is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive distribution network covering 25 provinces [3][4]. - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers, enhancing its supply chain capabilities [3][4]. Industry Context - The biopharmaceutical industry in China is recognized as a strategic sector, crucial for national health and security, and is currently undergoing significant structural adjustments [3][4]. - Government policies are aimed at encouraging innovation, optimizing procurement rules, and improving medical insurance payments, which are expected to drive market growth [3][4]. Research and Development - The company invested CNY 1.15 billion in R&D, accounting for 9.44% of its pharmaceutical manufacturing revenue [4][5]. - A total of 56 new drug applications were accepted for clinical trials, including 44 innovative drug projects [4][5]. - The company is advancing several key projects in various therapeutic areas, including hypertension and neurodegenerative diseases [5][6]. Commercial Strategy - The company is enhancing its digital transformation and supply chain efficiency, aiming to provide integrated healthcare solutions [12][13]. - It has launched a new retail strategy that combines traditional and online sales channels, achieving significant growth in e-commerce sales [12][13]. - The company has established a comprehensive import service system, increasing its sales revenue from imported products by 11.7% [12][13]. Corporate Governance and Investor Relations - The company emphasizes long-term stable cash dividends and shareholder returns, having distributed CNY 1.37 billion in dividends for the previous year [15][16]. - It has implemented governance improvements in line with regulatory requirements, including the addition of a female independent director [16][17]. - The company maintains strong communication with investors, ensuring transparency and engagement through various channels [17][18].

Core Viewpoint - Shanghai Pharmaceuticals Holding Co., Ltd. reported a revenue of 141.59 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.56% [5] - The net profit attributable to shareholders reached 4.46 billion RMB, a significant increase of 51.56% compared to the previous year, primarily due to a one-time special gain from accounting changes [5] - The company continues to enhance its core competitiveness and innovation capabilities, evidenced by its inclusion in the Fortune Global 500 and the list of the world's most valuable pharmaceutical brands [5] Financial Performance - Total assets at the end of the reporting period amounted to 238.07 billion RMB, an increase of 7.62% from the previous year [4] - The total profit for the period was 6.82 billion RMB, representing a growth of 41.45% year-on-year [4] - The net profit after deducting non-recurring gains was 2.71 billion RMB, a decrease of 22.38% compared to the previous year [4] Business Segments - Pharmaceutical manufacturing segment reported sales of 12.16 billion RMB, down 4.50% year-on-year, while the pharmaceutical distribution segment achieved sales of 129.43 billion RMB, up 2.17% [5] - The company has a robust pipeline with 56 new drug applications accepted for clinical trials, including 44 innovative drugs [6][7] Research and Development - R&D investment reached 1.15 billion RMB, accounting for 9.44% of the pharmaceutical manufacturing revenue [5] - The company is focusing on six major therapeutic areas: immunology, neurology, oncology, cardiovascular, digestive, and anti-infection [8] Strategic Initiatives - The company is advancing its transformation in pharmaceutical sales, enhancing operational efficiency through digitalization and compliance management [9] - Shanghai Pharmaceuticals is also expanding its new retail strategy, integrating online and offline channels to enhance customer engagement and sales [12][14] Market Position - The company has established strategic partnerships with various innovative pharmaceutical companies, leading to a 22.6% increase in sales from innovative drug business [13] - The company aims to strengthen its supply chain and import services, achieving a sales revenue of 17.5 billion RMB from imported products, a growth of 11.7% [13]

Group 1: Report Overview - The report is about a research on Shuyu Pingmin in the pharmaceutical commerce industry on August 29, 2025 [1][2] Group 2: Research Participants - Participating research institutions include Northeast Securities, CITIC Securities, China Merchants Securities, Guojin Securities, CITIC Construction, etc [2] Group 3: Company Performance in H1 2025 - The company's cumulative operating income from January to June 2025 was 4.881 billion yuan, a year - on - year increase of 1.30%; the net profit attributable to the parent company's shareholders was 36.2509 million yuan, a year - on - year increase of 49.83% [24] - Affected by industry policies and regulatory environment changes, the company's overall operating income growth slowed down, and the gross profit margin decreased by 1.56% year - on - year. However, the gross profit margin increased by 3.45% quarter - on - quarter compared to H2 2024 [24][25] - The company optimized the store network layout, adjusted the operating area, and optimized lease contract terms. The expense - to - sales ratio was optimized by 1.16% year - on - year [24] - As of the end of June 2025, the company had 9,042 stores in Shandong, Liaoning, Heilongjiang, Fujian, Henan, Gansu and other regions, including 5,072 direct - operated stores and 3,970 franchised stores [25] Group 4: Investor Q&A Impact of Prescription Out - dispensing Policy and Response - In Shandong, the tightening of the national policy has a relatively limited impact on the company. The company's coordinated business in Shandong has achieved a slight increase [25] Measures to Increase Market Share in Shandong - The company uses three core measures: mergers and acquisitions (3 M&A projects with 754 stores in Shandong in H1 2025), franchise upgrade (transforming some franchise stores to quasi - direct - operated franchise mode), and store optimization (closing loss - making stores, adjusting to meet diversified service needs, and piloting 4 "store + outpatient department" model drug - diagnosis stores) [26] Diversified Business Layout - Traditional non - drug categories include health foods, medical devices, and Chinese herbal health teas. Non - traditional categories include the growing health and beauty sector and lifestyle convenience products. The company also has industrial synergy through medical services and cross - border business, and focuses on private domain operations [26] Shandong - Outside M&A Expansion Plan - The company will moderately slow down the pace of M&A outside Shandong, while continuing the M&A plan in Shandong steadily. The current core task is to deepen the local business in Shandong [27] Sales of Self - owned Products - In H1 2025, the sales of self - owned products accounted for about 14%, a year - on - year increase of about 4%. The company expects the proportion to further increase [27] Long - and Medium - Term Online Business Strategy - The company's online business includes B2C, O2O, and private domain operations. B2C maintains stable profitability, O2O is profitable in Shandong and will develop steadily, and private domain operations are the key focus for future development [28] Outlook on Industry Clearance - The number of pharmacies will be gradually streamlined and optimized. With the deepening of the separation of pharmacy and medicine policy, industry concentration will increase, and inefficient pharmacies will be eliminated [29]

Report Information - Reported Company: Jianzhijia [17] - Industry: Pharmaceutical Commerce [2] - Research Date: August 29, 2025 [17] Core Views - The company is facing difficulties in obtaining medical insurance qualifications for newly opened stores, but is actively communicating with regulatory authorities. It is reducing its reliance on medical insurance and expanding non - medical insurance business, with the medical insurance settlement ratio dropping to 40% in H1 2025, a 4% year - on - year decrease [24]. - Through category adjustment, the company has achieved certain results. The proportion of prescription drug revenue structure decreased by 2.31%, while non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26]. Summary by Directory 01. Research Basic Situation - Research Object: Jianzhijia [17] - Industry: Pharmaceutical Commerce [17] - Reception Time: 2025 - 08 - 29 [17] - Reception Personnel: Chairman and General Manager Lan Bo, Financial Controller and Board Secretary Li Heng, Independent Director Guan Yunhong [17] 02. Detailed Research Institutions - Institutions: Investors and others [20] 03. Research Institution Proportion - No relevant content provided 04. Main Content Data - **Category Structure Change**: Newly opened stores in some areas have difficulties in obtaining medical insurance qualifications. The company is actively communicating with regulatory authorities. In H1 2025, the medical insurance settlement ratio was 40%, a 4% year - on - year decrease. The proportion of prescription drug revenue structure decreased by 2.31%, non - prescription drugs increased by 1.77%, and non - drug revenue structure increased by 0.55%. Inventory value decreased by 599 million yuan [24]. - **Online Business**: The company's online business has been profitable for a long time. In H1 2025, the online platform's total operating income was 1,318,588,700 yuan, a 13.13% year - on - year increase, and the operating ratio increased from 25.99% to 29.59% [26].

Core Viewpoint - The company, 华人健康, has completed the registration of business changes and the filing of its articles of association, obtaining a new business license from the Hefei Market Supervision Administration [1] Group 1 - The business change registration was completed on August 29, 2025 [1] - The new registered address is 123 Hebei Road, Baohe District, Hefei City, Anhui Province [1]

证券日报网讯 8月29日晚间，南京医药发布公告称，2025年半年度公司实现营业收入27，967，411， 701.62元，同比增长2.70%；归属于上市公司股东的净利润为291，276，712.36元，同比下降6.44%。 （编辑 何成浩） ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 9.699 billion yuan, representing a year-on-year decrease of 24.45% [1] - The net profit attributable to shareholders of the listed company was 107 million yuan, down 36.24% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 96.2624 million yuan, a decrease of 9.84% year-on-year [1] - The basic earnings per share were 0.37 yuan [1]